CEO and President of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Jeffrey W. Albers (insider trades) sold 20,000 shares of BPMC on 03/23/2020 at an average price of $52.1 a share. The total sale was $1 million.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $3.12 billion; its shares were traded at around $57.68 with and P/S ratio of 42.53. GuruFocus has detected 2 severe warning signs with Blueprint Medicines Corp. .
CEO Recent Trades:
- CEO and President Jeffrey W. Albers sold 20,000 shares of BPMC stock on 03/23/2020 at the average price of $52.1. The price of the stock has increased by 10.71% since.
- CEO and President Jeffrey W. Albers sold 2,277 shares of BPMC stock on 03/09/2020 at the average price of $51.97. The price of the stock has increased by 10.99% since.
CFO Recent Trades:
- CFO Michael Landsittel sold 400 shares of BPMC stock on 03/09/2020 at the average price of $51.97. The price of the stock has increased by 10.99% since.
Directors and Officers Recent Trades:
- Chief Scientific Officer Marion Dorsch sold 1,214 shares of BPMC stock on 03/23/2020 at the average price of $52.49. The price of the stock has increased by 9.89% since.
- Principal Accounting Officer Ariel Hurley sold 253 shares of BPMC stock on 03/09/2020 at the average price of $51.94. The price of the stock has increased by 11.05% since.
- Chief Medical Officer Anthony L. Boral sold 536 shares of BPMC stock on 03/09/2020 at the average price of $51.97. The price of the stock has increased by 10.99% since.
- Chief Scientific Officer Marion Dorsch sold 536 shares of BPMC stock on 03/09/2020 at the average price of $51.99. The price of the stock has increased by 10.94% since.
- Chief People Officer Debra Durso-bumpus sold 432 shares of BPMC stock on 03/09/2020 at the average price of $51.94. The price of the stock has increased by 11.05% since.
For the complete insider trading history of BPMC, click here
.
